Moirai Orthopaedics is a brand that is committed to providing exceptional treatment for serious orthopaedic medical conditions, with a focus on improving patient outcomes. They have developed an advanced, minimally-invasive surgical system called Pyrocarbon Implant Replacement (PIR) for the treatment of degenerative and arthritic knee disorders. The PIR is specifically designed to address symptomatic cartilage defects of the anterior or central medial femoral condyle and the patellofemoral joint.

This innovative system consists of a pyrocarbon articular resurfacing implant with hydroxylapatite coating for fixation. Moirai Orthopaedics understands the prevalence of articular cartilage defects and the limitations of current treatment options, which is why they have developed the PIR to provide a superior alternative. With benefits such as pain relief, restored function, and minimal damage to host bone and tissue, the PIR offers a shorter operative and rehabilitation time for most patients.

Additionally, Moirai Orthopaedics recognizes the market potential for the PIR, targeting a $2 billion market by addressing the needs of the 35-65-year-old demographic who may not be suitable for existing regenerative therapies or total knee replacement. With FDA approval to initiate clinical studies, Moirai Orthopaedics is at the forefront of orthopaedic innovation, revolutionizing the way cartilage defects are treated